Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Exchange Rate Effect: 2017-2022

Historic Exchange Rate Effect for Protagonist Therapeutics (PTGX) over the last 5 years, with Dec 2022 value amounting to $75,000.

  • Protagonist Therapeutics' Exchange Rate Effect rose 240.91% to $75,000 in Q4 2022 from the same period last year, while for Dec 2022 it was -$90,000, marking a year-over-year increase of 28.57%. This contributed to the annual value of -$90,000 for FY2022, which is 28.57% up from last year.
  • According to the latest figures from Q4 2022, Protagonist Therapeutics' Exchange Rate Effect is $75,000, which was up 142.86% from -$175,000 recorded in Q3 2022.
  • In the past 5 years, Protagonist Therapeutics' Exchange Rate Effect registered a high of $123,000 during Q3 2020, and its lowest value of -$175,000 during Q3 2022.
  • In the last 3 years, Protagonist Therapeutics' Exchange Rate Effect had a median value of $1,000 in 2020 and averaged -$3,417.
  • Over the last 5 years, Protagonist Therapeutics' Exchange Rate Effect had its largest YoY gain of 1,244.44% in 2020, and its largest YoY loss of 1,000.00% in 2020.
  • Quarterly analysis of 5 years shows Protagonist Therapeutics' Exchange Rate Effect stood at -$87,000 in 2018, then plummeted by 43.68% to -$125,000 in 2019, then skyrocketed by 116.80% to $21,000 in 2020, then grew by 4.76% to $22,000 in 2021, then skyrocketed by 240.91% to $75,000 in 2022.
  • Its Exchange Rate Effect was $75,000 in Q4 2022, compared to -$175,000 in Q3 2022 and -$19,000 in Q2 2022.